{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:59:22Z","timestamp":1790395162195,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T00:00:00Z","timestamp":1308009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic> 2011; <jats:bold>34:<\/jats:bold> 374\u2013383<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Imbalances in gut luminal bacteria may contribute to the pathogenesis of irritable bowel syndrome (IBS).<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To explore select bacteriological and anti\u2010inflammatory effects of mesalazine (mesalamine; 5\u2010aminosalicylic acid or 5ASA) and their relation to potential therapeutic effects in IBS.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Prospective pilot study of 12 women with diarrhoea\u2010predominant IBS. Patients received oral mesalazine (1.5\u2003g b.d.) for 4\u2003weeks followed by a 4\u2010week washout phase. Molecular profiling of stool bacterial communities and IBS symptoms were assessed before, during and after mesalazine treatment. Colonic mucosal biopsies were assessed for proteolytic activity. Qualitative and quantitative effects of mesalazine on stool microbiota, mucosal proteolytic activity and IBS symptoms were assessed.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Faecal bacteria decreased by 46% on mesalazine treatment (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.014), but returned to baseline during washout. <jats:italic>Firmicutes<\/jats:italic> and <jats:italic>Bacteroidetes<\/jats:italic> represented 95% of identified phylotypes, with a trend towards an increase in the proportion of <jats:italic>Firmicutes<\/jats:italic> at week 4 in symptomatic responders [median (IQR) 14% (49) increase] compared with nonresponders [median 5% (11) decrease, <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.088]. Rectosigmoid mucosal proteolytic activity did not change between baseline and treatment [median 23.2 (17.9) vs. 19.5 (46.7) mU activity\/mg tissue, <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.433]. Eight of 12 (67%) patients responded favourably to mesalazine based on a global relief questionnaire, with significant decreases in days with discomfort and increases in bowel movement satisfaction.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Mesalazine treatment is associated with a decrease in faecal bacteria abundance and rebalancing of the major constituents of the microbiota. Further study of the bacteriological and anti\u2010inflammatory properties of mesalazine in IBS is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2011.04732.x","type":"journal-article","created":{"date-parts":[[2011,6,15]],"date-time":"2011-06-15T10:57:16Z","timestamp":1308135436000},"page":"374-383","source":"Crossref","is-referenced-by-count":83,"title":["Mesalazine (5\u2010aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea\u2010predominant irritable bowel syndrome"],"prefix":"10.1111","volume":"34","author":[{"given":"C. N.","family":"Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vergnolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Surette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. P.","family":"Rioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37095"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03801.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.53.1.1"},{"key":"e_1_2_6_5_2","first-page":"185","article-title":"The fecal microbial population in the irritable bowel syndrome","volume":"5","author":"Balsari A","year":"1982","journal-title":"Microbiologica"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.005"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40312.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsim.2004.08.009"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i12.1802"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01869.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.167270"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004409"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2010.4"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.039"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29255"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.048876"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.140210"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0696"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01300753"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04041.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20876"},{"key":"e_1_2_6_22_2","first-page":"A663","article-title":"Aminosalicylates alter the dominant phylogenetic profile of fecal bacteria in mice","volume":"128","author":"Rioux KP","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20003"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1078\/0723-2020-00060"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.63.11.4516-4522.1997"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00062-07"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409535102"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.142318000.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.25.14863"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01640.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-007-0074-3"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01678.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528509089704"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110591"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.66.8.3616-3620.2000"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-2920.2005.00959.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.8-4-417"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb05612.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.08.008"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03361.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.68.7.3401-3407.2002"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-2920.2009.01900.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/089106001750462669"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04732.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2011.04732.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:39:31Z","timestamp":1697431171000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04732.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,14]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1111\/j.1365-2036.2011.04732.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04732.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,14]]}}}